Anebulo

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biotechnology company focused on treatments for cannabinoid-related conditions, announced today that the first participants have been dosed in its Phase 1 single ascending dose (SAD) clinical trial evaluating an intravenous (IV) formulation of selonabant. Study Design and Purpose The randomized, double-blind, … [Read more...] about Anebulo Launches Phase 1 Trial of IV Selonabant Targeting Cannabis Toxicity